Health
Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)
PRINCETON, N.J., September 25, 2025--Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu®...
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/a1ea6c187379f0852023c0f76e0fd076"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OOk3.6Le81Ra1hJndWiJoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a1ea6c187379f0852023c0f76e0fd076","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/raD5Y7G_AjkjwgvcT2.o8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a1ea6c187379f0852023c0f76e0fd076","width":1200,"height":165}},"lazy":false},{"type":"text","content":"Eliquis Offered to Cash-Paying Patients at More Than 40% Discount to Current List Price, Sotyktu at More Than 80% Discount to Current List Price","length":144,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., September 25, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its direct-to-patient offerings, providing eligible U.S. patients with steeply discounted prices for Eliquis® (apixaban) and Sotyktu® (deucravacitinib). Eligible cash-pay patients can now purchase these medicines directly from BMS and significantly lower their out-of-pocket costs.","length":400,"tagName":"p"},{"type":"text","content":"Beginning January 2026, Sotyktu, BMS’ medicine for moderate-to-severe plaque psoriasis, will be offered through the new BMS Patient Connect platform, which follows the launch of our Bristol Myers Squibb-Pfizer Alliance program for Eliquis® (apixaban) earlier this month. The platform will offer Sotyktu at more than 80% less than the current list price.","length":353,"tagName":"p"},{"type":"text","content":""We are proud to now offer Sotyktu at a lower price via BMS Patient Connect, our new direct-to-patient platform designed to make our innovative medicines more accessible and affordable for patients living with serious conditions," said Christopher Boerner, Ph.D., board chair and CEO of Bristol Myers Squibb. "We are taking a leading role in removing barriers, providing transparency and lowering out-of-pocket costs so patients in the United States can get the treatments they need – delivered directly to their door, wherever they ...